Montreal, Quebec — February 10, 2026 — Leads & Copy — Defence Therapeutics Inc., a biotechnology company trading under the symbols (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF), has reported on its Scientific Advisory Board (SAB) meeting held on January 30, 2026, which focused on advancing the strategic positioning of Accum® for antibody-drug conjugate (ADC) applications.
The meeting facilitated an exchange of expertise in ADC chemistry and development, experimental design and translational science, and value creation and partnering strategy, enabling an in-depth discussion on Accum®’s role in improving intracellular delivery of ADC payloads. The discussion focused on identifying scientific questions, refining development priorities, and aligning data generation with the expectations of future clinical and pharmaceutical partners.
According to Maxime Parisotto, PhD, Chief Scientific Officer of Defence Therapeutics, the discussion helped sharpen the company’s scientific focus and strategic direction. Parisotto added that the insights shared by the advisors are directly informing how the company is designing its next studies, ensuring that it generates the data that matter most to advance Accum® toward the clinic and position the platform for meaningful partnerships.
Rob Leanna, PhD, contributed his experience in ADC development, drug-linker chemistry, and clinical advancement shaped through his tenure at AbbVie. Danny Chui, PhD, brought insight into ADC design and translational science informed by his work at Zymeworks, Abdera Therapeutics, and Kairos Therapeutics. Brendan Hussey, PhD, contributed a value-creation and partnering perspective grounded in clinical development, strategy, and capital formation. Together, their input is guiding the next phase of Accum® development as the platform advances toward clinical translation and strategic partnerships.
As a result of this dialogue, Defence Therapeutics is refining its Accum® ADC development roadmap to better align platform capabilities with clinical development requirements and partnering considerations, with the goal of enabling more effective and better-tolerated ADC therapies. This approach reinforces Accum®’s potential as a next-generation intracellular delivery solution for complex biologics.
Defence Therapeutics is committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies.
To explore partnering opportunities or schedule a meeting, please contact info@defencetherapeutics.com.
Source: Defence Therapeutics Inc.
